Information on the monitoring and treatment of early T1D including relevant resources available for download
| Monitoring in Early T1D Resources | Date published | File/s |
|---|---|---|
| Consensus guidance for monitoring individuals with islet autoantibody‑positive pre‑stage 3 type 1 diabetes | 24 June 2024 |
|
| Highlighting the new consensus guidelines for managing people at risk of, and with early-stage type 1 diabetes—Relevance to clinical care in the UK | 23 December 2024 |
|
| Managing adults with screen-detected islet autoantibody positivity: a pragmatic framework | November 2025 | |
| UK best practice recommendations for children and young people <18 years with pre-stage 3 type 1 diabetes, on behalf of the British Society for Paediatric Endocrinology and Diabetes (BSPED) |
July 2025 |
|
Treatment in pre-type one diabetes.
| Treatment in Early T1D | Date published | File/s |
|---|---|---|
| Consensus statement: Pediatric Endocrine Society Statement on Considerations for Use of Teplizumab (Tzield™) in Clinical Practice | 30 April 2024 |
|
| MHRA prescribing information for healthcare professionals Tzield 2 mg/2 mL concentrate for solution for infusion |
Updated: 15 August 2025 |
|
| Package leaflet: Information for the patient Tzield 2 mg/2 mL concentrate for solution for infusion |
|
